Effects of FK506 and cyclosporin A on proliferation, histamine release and phenotype of murine mast cells.
Using mouse peritoneal cavity mast cells, we investigated the effects of FK506 and cyclosporin A (CsA) on cell proliferation and histamine release induced by anti-IgE antibody, calcium ionophore (A23 187), or neuropeptide (substance P). Both FK506 and CsA inhibited cytokine-dependent mast cell proliferation in a dose-dependent manner. The inhibitory effects of these compounds on mast cell proliferation was reversible; the removal of the chemicals from the incubation medium resulted in the reinitiation of mast cell proliferation. Flow cytometric analysis suggested that the inhibitory effect of FK506 and CsA was mostly due to G1/S boundary block, although a significant number of G2-arrested cells were also observed following FK506 treatment. Both FK506- and CsA-treated mast cells showed a similar inhibition of histamine release induced by A23187. However, CsA at higher concentrations inhibited the histamine release induced by anti-IgE antibody or substance P more markedly than FK506. Cellular histamine content was decreased by CsA treatment while FK506 had no effect. The staining properties of peritoneal mast cells changed from connective tissue-type mast cell-like to mucosal mast cell-like during CsA treatment but not during FK506 treatment. Thus FK506 and CsA have different effects on mast cell proliferation as well as histamine release, that might be associated with a phenotypic change of the cells during culture.
Toyota
N
N
Department of Dermatology, Asahikawa Medical College, Hokkaido, Japan.
Hashimoto
Y
Y
Matsuo
S
S
Kitamura
Y
Y
Iizuka
H
H
D000818:Animals; D000001:Calcimycin / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D016572:Cyclosporine / Q000494:pharmacology*; D006636:Histamine Release / Q000187:drug effects*; D007073:Immunoglobulin E / Q000276:immunology; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007476:Ionophores / Q000494:pharmacology; D008407:Mast Cells / Q000187:drug effects*; D051379:Mice; D008815:Mice, Inbred Strains; D010529:Peritoneal Cavity / Q000166:cytology; D010641:Phenotype; D013373:Substance P / Q000494:pharmacology; D016559:Tacrolimus / Q000494:pharmacology*
D007166:Immunosuppressive Agents; D007476:Ionophores; D013373:Substance P; D007073:Immunoglobulin E; D000001:Calcimycin; D016572:Cyclosporine; D016559:Tacrolimus